Neoleukin Therapeutics, Inc. approved a reduction in force of approximately 70% and a re-prioritization of focus to seek strategic alternatives, with estimated costs of $2.5-3.0 million, including severance and benefits, contract termination costs, and other expenses. The CEO, Jonathan G. Drachman, will resign effective March 31, 2023, and will receive severance payments, healthcare coverage, and accelerated vesting of options.